ArticleAntimicrobial resistance and infection control2019
A multimodal intervention program to control a long-term
Article in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Active surveillance cultures and cohorting for carbapenem-resistantInfection control and hospital epidemiology · 2026Article
- Effect of daily pillow cover replacement on the incidence of carbapenem resistant Acinetobacter baumannii (CRAB) in the medical intensive care units (MICU): a comparative study.Antimicrobial resistance and infection control · 2026Article
- A decade of genomic and phenotypic adaptation of carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Fluopsin C Promotes Biofilm Removal of XDRAntibiotics (Basel, Switzerland) · 2024Article
- Complex Infection-Control Measures with Disinfectant Switch Help the Successful Early Control of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria andAntibiotics (Basel, Switzerland) · 2024Review
- Non-thermal obliteration of critically ranked carbapenem-resistant Acinetobacter baumannii and its resistance gene in a batch atmospheric plasma reactor.Environmental science and pollution research international · 2024Article
- Molecular and clinical epidemiology of carbapenem resistantThe Lancet regional health. Western Pacific · 2024Article
- Tailoring Interventions for Control of Endemic Carbapenem-ResistantOpen forum infectious diseases · 2024Article
- Contribution of active surveillance cultures to the control of hospital-acquired carbapenem-resistantInfection control and hospital epidemiology · 2024Article
- Molecular and clinical epidemiology of carbapenem resistantThe Lancet regional health. Western Pacific · 2023Article
- Antibiotic utilisation and resistance over the first decade of nationally funded antimicrobial stewardship programmes in Singapore acute-care hospitals.Antimicrobial resistance and infection control · 2023Observational
- Carbapenem-ResistantCase reports in infectious diseases · 2023Article
- Is It Possible to Eradicate Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Review
- The Impact of Antimicrobial Stewardship and Infection Control Interventions onAntibiotics (Basel, Switzerland) · 2022Article
- High lethality rate of carbapenem-resistant Acinetobacter baumannii in Intensive Care Units of a Brazilian hospital: An epidemiologic surveillance study.Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- Virulence Potential and Treatment Options of Multidrug-Resistant (MDR)Microorganisms · 2021Review
- A five-component infection control bundle to permanently eliminate a carbapenem-resistant Acinetobacter baumannii spreading in an intensive care unit.Antimicrobial resistance and infection control · 2021Article
- Bacterial survival on inanimate surfaces: a field study.BMC research notes · 2021Article
- Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Design: Quasi-experimental intervention study based on open cohorts.Setting: Public tertiary referral centre. Period: January 2009-August 2017.Intervention: multifaceted program based on environmental decontamination, hand hygiene, antimicrobial stewardship, contact precautions, active surveillance, weekly reports and regular meetings.Analysis: joinpoint regression and interrupted time-series analysis. Results: The intervention was successfully implemented. Through the study period, the compliance with contact precautions changed from 0 to 100% and with hand hygiene, from 41.8 to 82.3%. Between 2012 and 2016, the antibiotic consumption decreased from 165.35 in to 150.44 daily-defined doses/1000 patients-days in the ICU. The incidence density of MDR-Ab in the ICU was 10.9 cases/1000 patients-days at the beginning of the intervention. After this moment, the evolution of the incidence density of MDR-Ab was: between months 0 and 6°, it remained stable; between months 7° and 10°: there was an intense decrease, with an average monthly percentage change (AMPC) = - 30.05%; from 11° month until the end, the decrease was lighter but continuous (AMPC:-2.77%), achieving an incidence density of 0 cases/1000 patients-days on the 18° month, without any new case for 12 months. From the 30° month until the end of the study period, several little outbreaks of MDR-Ab were detected, all of them rapidly controlled. The strains of MDR-Ab isolated during these outbreaks were not clonally related with the previously endemic one, which supports its eradication from the environmental reservoirs. Conclusion: The multicomponent intervention performed by a multidisciplinary team was effective to eradicate the endemic MDR-Ab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.